In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Fifty years ago, 20 of the world's brightest people tried to predict life in 2024. They got an awful lot wrong.

"Don't risk your health trying to get healthy," she said. Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...